On March 24, 2022 Genagon Therapeutics reported that the European Patent Office has issued the Company European Patent No. 3568142, titled "Therapeutic Agents" (Press release, Genagon Therapeutics, MAR 24, 2022, View Source;utm_medium=rss&utm_campaign=patent-granted [SID1234610882]). The patent covers, among other things, the use of a polypeptide capable of binding to proteins in the TGFb superfamily. These claims protect inventions which are central to the Company’s programs for treating cancer and strengthen its main business focus.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CEO Moa Fransson comments: "These claims protect inventions which are central to the Company’s programs for treating cancer and strengthen its main business focus".